手足口病:叙述性回顾。

IF 1.2 Q4 PHARMACOLOGY & PHARMACY
Alexander K C Leung, Joseph M Lam, Benjamin Barankin, Kin Fon Leong, Kam Lun Hon
{"title":"手足口病:叙述性回顾。","authors":"Alexander K C Leung,&nbsp;Joseph M Lam,&nbsp;Benjamin Barankin,&nbsp;Kin Fon Leong,&nbsp;Kam Lun Hon","doi":"10.2174/1570180820666221024095837","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hand, foot, and mouth disease is a common viral disease in childhood. Because the disease has the potential to reach epidemic levels and mortality is high in some countries, early recognition of this disease is of paramount importance.</p><p><strong>Objective: </strong>This purpose of this article is to familiarize pediatricians with the clinical manifestations and management of hand, foot, and mouth disease.</p><p><strong>Methods: </strong>A search was conducted in February 2022 in PubMed Clinical Queries using the key term \"hand, foot, and mouth disease\". The search strategy included all clinical trials, observational studies, and reviews published within the past 10 years. Only papers published in English were included in this review.</p><p><strong>Results: </strong>Hand, foot, and mouth disease is characterized by a painful oral enanthem and asymptomatic exanthem on the palms and soles. Children younger than 5 years are most commonly affected. Hand, foot, and mouth disease caused by enterovirus A71 is more severe and has a higher rate of complications than that attributed to other viruses such as coxsackievirus A16. Circulatory failure secondary to myocardial impairment and neurogenic pulmonary edema secondary to brainstem damage are the main causes of death. Fortunately, the disease is usually benign and resolves in 7 to10 days without sequelae. Given the self-limited nature of most cases, treatment is mainly symptomatic and supportive. Intravenous immunoglobulin should be considered for the treatment of severe/complicated hand, foot, and mouth disease and has been recommended by several national and international guideline committees. Currently, there are no specific antiviral agents approved for the treatment of the disease. Drugs such as ribavirin, suramin, mulberroside C, aminothiazole analogs, and sertraline have emerged as potential candidates for the treatment of hand, foot, and mouth disease. Vaccination of susceptible individuals in high-risk areas and good personal hygiene are important preventative measures to combat the disease.</p><p><strong>Conclusion: </strong>Familiarity of the disease including its atypical manifestations is crucial so that a correct diagnosis can be made, and appropriate treatment initiated. A timely diagnosis can help avoid contact with the affected individual and decrease the risk of an outbreak.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Hand, Foot, and Mouth Disease: A Narrative Review.\",\"authors\":\"Alexander K C Leung,&nbsp;Joseph M Lam,&nbsp;Benjamin Barankin,&nbsp;Kin Fon Leong,&nbsp;Kam Lun Hon\",\"doi\":\"10.2174/1570180820666221024095837\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Hand, foot, and mouth disease is a common viral disease in childhood. Because the disease has the potential to reach epidemic levels and mortality is high in some countries, early recognition of this disease is of paramount importance.</p><p><strong>Objective: </strong>This purpose of this article is to familiarize pediatricians with the clinical manifestations and management of hand, foot, and mouth disease.</p><p><strong>Methods: </strong>A search was conducted in February 2022 in PubMed Clinical Queries using the key term \\\"hand, foot, and mouth disease\\\". The search strategy included all clinical trials, observational studies, and reviews published within the past 10 years. Only papers published in English were included in this review.</p><p><strong>Results: </strong>Hand, foot, and mouth disease is characterized by a painful oral enanthem and asymptomatic exanthem on the palms and soles. Children younger than 5 years are most commonly affected. Hand, foot, and mouth disease caused by enterovirus A71 is more severe and has a higher rate of complications than that attributed to other viruses such as coxsackievirus A16. Circulatory failure secondary to myocardial impairment and neurogenic pulmonary edema secondary to brainstem damage are the main causes of death. Fortunately, the disease is usually benign and resolves in 7 to10 days without sequelae. Given the self-limited nature of most cases, treatment is mainly symptomatic and supportive. Intravenous immunoglobulin should be considered for the treatment of severe/complicated hand, foot, and mouth disease and has been recommended by several national and international guideline committees. Currently, there are no specific antiviral agents approved for the treatment of the disease. Drugs such as ribavirin, suramin, mulberroside C, aminothiazole analogs, and sertraline have emerged as potential candidates for the treatment of hand, foot, and mouth disease. Vaccination of susceptible individuals in high-risk areas and good personal hygiene are important preventative measures to combat the disease.</p><p><strong>Conclusion: </strong>Familiarity of the disease including its atypical manifestations is crucial so that a correct diagnosis can be made, and appropriate treatment initiated. A timely diagnosis can help avoid contact with the affected individual and decrease the risk of an outbreak.</p>\",\"PeriodicalId\":29815,\"journal\":{\"name\":\"Recent Advances in Inflammation & Allergy Drug Discovery\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recent Advances in Inflammation & Allergy Drug Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1570180820666221024095837\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent Advances in Inflammation & Allergy Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1570180820666221024095837","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

摘要

背景:手足口病是儿童常见的病毒性疾病。由于这种疾病有可能达到流行病的程度,而且在一些国家死亡率很高,因此及早发现这种疾病至关重要。目的:本文的目的是让儿科医生熟悉手足口病的临床表现和处理。方法:于2022年2月在PubMed临床查询中使用关键词“手足口病”进行检索。检索策略包括过去10年内发表的所有临床试验、观察性研究和综述。本综述只收录了以英文发表的论文。结果:手足口病的特点是口腔疼痛,手掌和脚底无症状渗漏。5岁以下儿童最常受影响。与柯萨奇病毒A16等其他病毒相比,由肠道病毒A71引起的手足口病更为严重,并发症发生率更高。继发于心肌损伤的循环衰竭和继发于脑干损伤的神经源性肺水肿是主要的死亡原因。幸运的是,这种疾病通常是良性的,在7到10天内消退,没有后遗症。鉴于大多数病例的自限性,治疗主要是对症和支持性的。静脉注射免疫球蛋白应被考虑用于治疗严重/复杂的手足口病,并已被几个国家和国际指南委员会推荐。目前,还没有特定的抗病毒药物被批准用于治疗这种疾病。利巴韦林、舒拉明、桑葚苷C、氨基噻唑类似物和舍曲林等药物已成为治疗手足口病的潜在候选药物。为高危地区的易感人群接种疫苗和保持良好的个人卫生是防治该病的重要预防措施。结论:熟悉本病及其不典型表现是正确诊断和适当治疗的关键。及时诊断有助于避免与受影响的个人接触,并降低爆发的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Hand, Foot, and Mouth Disease: A Narrative Review.

Background: Hand, foot, and mouth disease is a common viral disease in childhood. Because the disease has the potential to reach epidemic levels and mortality is high in some countries, early recognition of this disease is of paramount importance.

Objective: This purpose of this article is to familiarize pediatricians with the clinical manifestations and management of hand, foot, and mouth disease.

Methods: A search was conducted in February 2022 in PubMed Clinical Queries using the key term "hand, foot, and mouth disease". The search strategy included all clinical trials, observational studies, and reviews published within the past 10 years. Only papers published in English were included in this review.

Results: Hand, foot, and mouth disease is characterized by a painful oral enanthem and asymptomatic exanthem on the palms and soles. Children younger than 5 years are most commonly affected. Hand, foot, and mouth disease caused by enterovirus A71 is more severe and has a higher rate of complications than that attributed to other viruses such as coxsackievirus A16. Circulatory failure secondary to myocardial impairment and neurogenic pulmonary edema secondary to brainstem damage are the main causes of death. Fortunately, the disease is usually benign and resolves in 7 to10 days without sequelae. Given the self-limited nature of most cases, treatment is mainly symptomatic and supportive. Intravenous immunoglobulin should be considered for the treatment of severe/complicated hand, foot, and mouth disease and has been recommended by several national and international guideline committees. Currently, there are no specific antiviral agents approved for the treatment of the disease. Drugs such as ribavirin, suramin, mulberroside C, aminothiazole analogs, and sertraline have emerged as potential candidates for the treatment of hand, foot, and mouth disease. Vaccination of susceptible individuals in high-risk areas and good personal hygiene are important preventative measures to combat the disease.

Conclusion: Familiarity of the disease including its atypical manifestations is crucial so that a correct diagnosis can be made, and appropriate treatment initiated. A timely diagnosis can help avoid contact with the affected individual and decrease the risk of an outbreak.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
33
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信